CN116847874B - Dhodh抑制剂化合物在组合癌症疗法中的用途 - Google Patents

Dhodh抑制剂化合物在组合癌症疗法中的用途

Info

Publication number
CN116847874B
CN116847874B CN202180052749.9A CN202180052749A CN116847874B CN 116847874 B CN116847874 B CN 116847874B CN 202180052749 A CN202180052749 A CN 202180052749A CN 116847874 B CN116847874 B CN 116847874B
Authority
CN
China
Prior art keywords
lymphoma
compound
pharmaceutically acceptable
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180052749.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116847874A (zh
Inventor
J·科可
B·尼古拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN116847874A publication Critical patent/CN116847874A/zh
Application granted granted Critical
Publication of CN116847874B publication Critical patent/CN116847874B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180052749.9A 2020-08-27 2021-08-26 Dhodh抑制剂化合物在组合癌症疗法中的用途 Active CN116847874B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070984P 2020-08-27 2020-08-27
US63/070,984 2020-08-27
PCT/US2021/047778 WO2022047051A1 (en) 2020-08-27 2021-08-26 Use of a dhodh inhibitor compound in combination cancer therapy

Publications (2)

Publication Number Publication Date
CN116847874A CN116847874A (zh) 2023-10-03
CN116847874B true CN116847874B (zh) 2026-07-03

Family

ID=78000775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052749.9A Active CN116847874B (zh) 2020-08-27 2021-08-26 Dhodh抑制剂化合物在组合癌症疗法中的用途

Country Status (9)

Country Link
US (1) US20230285365A1 (cg-RX-API-DMAC7.html)
EP (1) EP4203950B1 (cg-RX-API-DMAC7.html)
JP (1) JP7734742B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230078997A (cg-RX-API-DMAC7.html)
CN (1) CN116847874B (cg-RX-API-DMAC7.html)
BR (1) BR112023003493A2 (cg-RX-API-DMAC7.html)
CA (1) CA3190511A1 (cg-RX-API-DMAC7.html)
ES (1) ES3063941T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022047051A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060390A1 (en) 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
CA3091792A1 (en) 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
BR112021012305A2 (pt) * 2018-12-21 2021-10-05 Les Laboratoires Servier Sas Formas cristalinas e salinas de um composto orgânico e composições farmacêuticas das mesmas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459184A (zh) * 2014-02-28 2017-02-22 詹森生物科技公司 与抗cd38抗体联用的组合疗法
WO2019164794A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
WO2020132471A1 (en) * 2018-12-21 2020-06-25 Agios Pharmaceuticals, Inc. Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694829T3 (es) 2013-02-25 2018-12-27 Aurigene Discovery Technologies Limited Derivados de benzotriazol trisustituido como inhibidores de dihidroorotato oxigenasa
CN106687139A (zh) * 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
WO2016166761A1 (en) * 2015-04-14 2016-10-20 Tiltan Pharma Ltd. Combination therapies and uses thereof in the treatment of cancer
CA3060390A1 (en) * 2017-04-24 2018-11-01 Aurigene Discovery Technologies Limited Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) * 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
WO2019197269A1 (en) * 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
KR20210003789A (ko) * 2018-05-04 2021-01-12 포톨라 파마슈티컬스, 인코포레이티드 림프종을 치료하는 방법
WO2020109625A1 (en) * 2018-11-30 2020-06-04 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459184A (zh) * 2014-02-28 2017-02-22 詹森生物科技公司 与抗cd38抗体联用的组合疗法
WO2019164794A1 (en) * 2018-02-20 2019-08-29 Agios Pharmaceuticals, Inc. Methods of use for trisubstituted benzotriazole derivatives
WO2020132471A1 (en) * 2018-12-21 2020-06-25 Agios Pharmaceuticals, Inc. Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Classical swine fever virus non-structural protein 4A recruits dihydroorotate dehydrogenase to facilitate viral replication";Zhao, BQ等;《JOURNAL OF VIROLOGY》;20240613;第1-24页 *
"Final results of phase II trial of doxorubicin HCI liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma";Straus, DJ等;《ANNALS OF ONCOLOGY》;20131126;第1-6页 *

Also Published As

Publication number Publication date
WO2022047051A1 (en) 2022-03-03
US20230285365A1 (en) 2023-09-14
CN116847874A (zh) 2023-10-03
EP4203950B1 (en) 2026-02-18
ES3063941T3 (en) 2026-04-21
BR112023003493A2 (pt) 2023-04-11
JP2023540206A (ja) 2023-09-22
JP7734742B2 (ja) 2025-09-05
EP4203950A1 (en) 2023-07-05
EP4203950C0 (en) 2026-02-18
KR20230078997A (ko) 2023-06-05
CA3190511A1 (en) 2022-03-03

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant